Thyrel Trh
FDA Announces Import of Injectable Nutrition Drugs »
"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.
TPN is an intravenous"...
Read the FDA Announces Import of Injectable Nutrition Drugs article »
Thyrel Trh
(Generic versions may still be available.)
CLINICAL PHARMACOLOGY
Pharmacologically, Thyrel TRH (protirelin) increases the release of the thyroid stimulating hormone (TSH) from the anterior pituitary. Prolactin release is also increased. It has recently been observed that approximately 65% of acromegalic patients tested respond with a rise in circulating growth hormone levels; the clinical significance is as yet not clear. Following intravenous administration, the mean plasma half-life of protirelin in normal subjects is approximately five minutes. TSH levels rise rapidly and reach a peak at 20 to 30 minutes. The decline in TSH levels takes place more slowly, approaching baseline levels after approximately three hours.
Last reviewed on RxList: 1/18/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Thyrel Trh Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.






